Upon its release in 1993, intensive insulin therapy was heralded as the new standard of care for all or most people with type 1 diabetes, although the study was limited to participants aged 13–39 years at entry with duration of diabetes of 1–15 years. The gene discussed is INS; the disease is diabetes mellitus.